Sarcopenic obesity and risk of cardio-cerebrovascular disease and mortality: a systematic review and meta-analysis
Pooled result · CCVD riskResult — go to the resultOdds ratio 2.06 95% CI 1.70–2.48Authors' conclusion
Sarcopenic obesity is associated with an increased risk of CCVD, and its long-term impact on CCVD mortality may be more evident in studies with larger sample sizes and extended follow-up periods. These findings underscore the need for well-designed prospective studies employing standardized diagnostic criteria and adequate follow-up to confirm the observed associations and clarify their clinical significance.
Study context
- Population
- Adults with vs without sarcopenic obesity in studies from PubMed, Embase, Web of Science, Cochrane Library and Chinese databases, inception to April 1, 2024
- Participants
- 575,942 adults28 studies
- Comparison
- Sarcopenic obesity vs no sarcopenic obesity
- Outcome
- Risk of cardio-cerebrovascular disease (CCVD)
Methodological detailsfixed- and random-effects models
- Fixed- and random-effects models
Pooled result
CCVD risk
Odds ratio
2.06
95% CI 1.70–2.48
P < 0.001
As reported in the abstract
Further pooled results
Cardio-cerebrovascular disease (CCVD), subgroup: sarcopenic obesity defined by muscle mass, muscle strength and BMI combined
- Increased risk of CCVD
- 9.22-fold
- Increased risk of CVD
- 2.10-fold
- No significant association with risk of stroke
- Subgroup analysis
CCVD mortality
- No significant overall association, 7 studies: OR (95% CI); I²; p
- 1.58 (0.99-2.53); I² = 92%; p = 0.05
- Random-effects or fixed-effects pooling
CCVD mortality, subgroup: studies with ≥5000 participants
- Significant association: OR (95% CI); p
- 1.76 (1.37-2.27); p < 0.01
- Subgroup analysis
CCVD mortality, subgroup: follow-up ≥10 years
- Significant association: OR (95% CI); p
- 1.54 (1.16-2.04); p < 0.01
- Subgroup analysis
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →